Expanding horizons of fecal microbiota transplantation: Beyond C. Difficile to treating other infections

Fecal Microbiota Transplantation (FMT) has surfaced as a revolutionary therapeutic method, mainly acknowledged for its success in treating recurrent Clostridioides difficile infections (CDI). By reinstating the gut's microbial diversity, FMT has shown recovery rates over 90% in individuals with recurrent CDI, providing a secure and economical alternative to conventional antibiotic treatments. In addition to CDI, the possible uses of FMT are broadening into different infectious diseases. Studies reveal hopeful results in tackling multidrug-resistant bacterial infections, where standard therapies frequently fall short. Moreover, FMT is under investigation for its potential to modify the gut microbiota to boost immune responses against viral pathogens, indicating a wider range of therapeutic opportunities. However, despite its promise, the extensive implementation of FMT encounters numerous obstacles. Guaranteeing standardized procedures for donor evaluation and stool preparation is vital to reduce risks associated with pathogen transmission. Regulatory structures must develop to keep pace with this emerging therapy, tackling ethical issues and ensuring patient security. Additionally, comprehending the long-term consequences of microbiota alteration remains a significant focus for future investigations. FMT is at the leading edge of groundbreaking treatments for infectious diseases, with its achievements in CDI paving the path for broader uses.